Skip to main content

Table 4 Correlation CD163+ TAMs in the tumour central area (TCA) or tumour-infiltrating front (TIF) with clinicopathological characteristics in HCC

From: Immunologic cellular characteristics of the tumour microenvironment of hepatocellular carcinoma drive patient outcomes

Variable CD163+/TCA CD163/TCA p value
No. of patients 42 16  
Patient age, years    0.177
 ≤ 60 13 (31.0%) 8 (50.0%)  
 > 60 29 (69.9%) 8 (50.0%)  
Gender    0.680
 Female 10 (76.2%) 3 (18.8%)  
 Male 32 (23.8%) 13 (81.2%)  
Local tumour recurrence    0.398
 Positive 11 (26.2%) 6 (37.5%)  
 Negative 31 (73.8%) 10 (62.5%)  
Overall tumour recurrence    0.320
 Positive 15 (35.7%) 8 (50.0%)  
 Negative 27 (64.3%) 8 (50.0%)  
Distant metastases    0.469
 Positive 7 (16.7%) 4 (25.0%)  
 Negative 35 (83.3%) 12 (75.0%)  
Multiple tumour nodules    0.016
 Positive 36 (85.7%) 9 (56.3%)  
 Negative 6 (14.3%) 7 (43.8%)  
Tumour size (mm)    0.438
 ≤ 50 9 (21.4%) 2 (12.5%)  
 > 50 33 (78.6%) 14 (87.5%)  
R status    0.695
 Positive 35 (15.1%) 2 (12.5%)  
 Negative 7 (84.9%) 14 (87.5%)  
Angioinvasion    0.311
 Positive 20 (47.6%) 10 (62.5%)  
 Negative 22 (52.4%) 6 (37.5%)  
Lymphangiosis carcinomatosa    0.656
 Positive 13 (31.0%) 4 (25.0%)  
 Negative 29 (69.0%) 12 (75.0%)  
Histologic differentiation    0.979
 Well 8 (19.0%) 3 (18.8%)  
 Moderate/poor 34 (81.0%) 13 (81.3%)  
Pathologic T stage    0.501
 T1/T2 22 (53.7%) 7 (43.8%)  
 T3/T4 19 (46.3%) 9 (56.3%)  
Pathologic N stage    0.470
 Positive 1 (02.4%) 1 (06.3%)  
 Negative 41 (97.6%) 15 (93.7%)  
No. of patients 19 39  
Lymphangiosis carcinomatosa    0.035
 Positive 9 (47.4%) 8 (20.5%)  
 Negative 10 (52.6%) 31 (79.5%)